These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

816 related items for PubMed ID: 15466208

  • 1. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B.
    Cancer Res; 2004 Oct 01; 64(19):7117-26. PubMed ID: 15466208
    [Abstract] [Full Text] [Related]

  • 2. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
    Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B.
    Cancer Res; 2005 Jan 01; 65(1):264-76. PubMed ID: 15665303
    [Abstract] [Full Text] [Related]

  • 3. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR, Bonavida B.
    Oncogene; 2005 Mar 24; 24(13):2121-43. PubMed ID: 15789036
    [Abstract] [Full Text] [Related]

  • 4. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.
    Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C, Bonavida B.
    Oncogene; 2004 Apr 29; 23(20):3530-40. PubMed ID: 15077178
    [Abstract] [Full Text] [Related]

  • 5. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
    Bonavida B, Vega MI.
    Drug Resist Updat; 2005 Apr 29; 8(1-2):27-41. PubMed ID: 15939340
    [Abstract] [Full Text] [Related]

  • 6. Activation of extracellular signal-regulated kinases ERK1 and ERK2 induces Bcl-xL up-regulation via inhibition of caspase activities in erythropoietin signaling.
    Mori M, Uchida M, Watanabe T, Kirito K, Hatake K, Ozawa K, Komatsu N.
    J Cell Physiol; 2003 May 29; 195(2):290-7. PubMed ID: 12652655
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
    Alas S, Emmanouilides C, Bonavida B.
    Clin Cancer Res; 2001 Mar 29; 7(3):709-23. PubMed ID: 11297268
    [Abstract] [Full Text] [Related]

  • 8. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
    Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA.
    Oncogene; 2007 Feb 08; 26(6):813-21. PubMed ID: 16909118
    [Abstract] [Full Text] [Related]

  • 9. Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis.
    Chetoui N, Sylla K, Gagnon-Houde JV, Alcaide-Loridan C, Charron D, Al-Daccak R, Aoudjit F.
    Mol Cancer Res; 2008 Jan 08; 6(1):42-52. PubMed ID: 18234961
    [Abstract] [Full Text] [Related]

  • 10. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
    Jazirehi AR, Vega MI, Bonavida B.
    Cancer Res; 2007 Feb 01; 67(3):1270-81. PubMed ID: 17283164
    [Abstract] [Full Text] [Related]

  • 11. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis.
    Jazirehi AR, Gan XH, De Vos S, Emmanouilides C, Bonavida B.
    Mol Cancer Ther; 2003 Nov 01; 2(11):1183-93. PubMed ID: 14617792
    [Abstract] [Full Text] [Related]

  • 12. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines.
    Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK.
    Cancer Res; 2004 Aug 01; 64(15):5186-92. PubMed ID: 15289323
    [Abstract] [Full Text] [Related]

  • 13. Flagellin and lipopolysaccharide stimulate the MEK-ERK signaling pathway in chicken heterophils through differential activation of the small GTPases, Ras and Rap1.
    Kogut MH, Genovese KJ, He H.
    Mol Immunol; 2007 Mar 01; 44(7):1729-36. PubMed ID: 17045653
    [Abstract] [Full Text] [Related]

  • 14. Gamma-tocotrienol-induced apoptosis in human gastric cancer SGC-7901 cells is associated with a suppression in mitogen-activated protein kinase signalling.
    Sun W, Wang Q, Chen B, Liu J, Liu H, Xu W.
    Br J Nutr; 2008 Jun 01; 99(6):1247-54. PubMed ID: 18081943
    [Abstract] [Full Text] [Related]

  • 15. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
    Yang R, Piperdi S, Gorlick R.
    Clin Cancer Res; 2008 Oct 15; 14(20):6396-404. PubMed ID: 18927278
    [Abstract] [Full Text] [Related]

  • 16. Serine protease inhibitor TPCK prevents Taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells.
    Huang Y, Sheikh MS, Fornace AJ, Holbrook NJ.
    Oncogene; 1999 Jun 10; 18(23):3431-9. PubMed ID: 10376521
    [Abstract] [Full Text] [Related]

  • 17. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.
    Mathas S, Rickers A, Bommert K, Dörken B, Mapara MY.
    Cancer Res; 2000 Dec 15; 60(24):7170-6. PubMed ID: 11156427
    [Abstract] [Full Text] [Related]

  • 18. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.
    Zhao WL, Wang L, Liu YH, Yan JS, Leboeuf C, Liu YY, Wu WL, Janin A, Chen Z, Chen SJ.
    Exp Hematol; 2007 Dec 15; 35(12):1801-11. PubMed ID: 17681667
    [Abstract] [Full Text] [Related]

  • 19. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.
    Bonavida B.
    Oncogene; 2007 May 28; 26(25):3629-36. PubMed ID: 17530016
    [Abstract] [Full Text] [Related]

  • 20. Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma.
    Schuierer MM, Bataille F, Weiss TS, Hellerbrand C, Bosserhoff AK.
    Oncol Rep; 2006 Sep 28; 16(3):451-6. PubMed ID: 16865242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.